Why the study?
Do novel oral anticoagulants (NOACs) prevent stroke and systemic embolism as effectively and safely as warfarin in patients with atrial fibrillation?
Population
Patients with atrial fibrillation at moderate to high risk of stroke, including those with risk factors such…
Comparison
Novel oral anticoagulants as a class… vs Dose-adjusted warfarin requiring regular…
Design
Review
Authors
Loading...
NOACs may be considered over warfarin in AF; confirms RCT summaries but leaves real-world applicability open.
Do novel oral anticoagulants (NOACs) prevent stroke and systemic embolism as effectively and safely as warfarin in patients with atrial fibrillation?
NOACs provide an effective, predictable, and convenient alternative to warfarin for stroke prevention in atrial fibrillation without the need for routine INR monitoring.
Bruce S. Stambler (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: